@prefix this: . @prefix sub: . @prefix prov: . @prefix dct: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix v: . @prefix d: . @prefix dv: . @prefix dr: . @prefix dcat: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB08831 v:identifier "DB08831"; v:namespace "drugbank"; v:uri "http://bio2rdf.org/drugbank:DB08831"; v:x-identifiers.org ; dv:drugbank-id "DB08831"; dv:x-cas ; dv:x-chebi ; dv:x-kegg ; dv:x-wikipedia ; dct:description "2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). By using positron emission tomography (PET), radiolabelled 2-deoxyglucose can determine glucose metabolism, which is altered in diseases such as cardiovascular disease, tumors, and Alzheimer's disease. Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent. Concerning the former, 2- deoxyglucose was used as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors (lung, breast, pancreas, head, neck, and gastric tumors). The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately, cell survival. With respect to antiviral therapy, 2-deoxyglucose was shown to be effective against herpes simplex virus by affecting the virus' ability to penetrate cells. As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. In this condition, 2-deoxyglucose represses the expression of certain proteins that are at high levels after a seizure. Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent."@en; dct:identifier "drugbank:DB08831"; dct:title "2-deoxyglucose"@en; a dv:Drug; rdfs:label "2-deoxyglucose [drugbank:DB08831]"@en; rdfs:seeAlso . } sub:provenance { sub:assertion prov:wasDerivedFrom . dr:bio2rdf.dataset.drugbank.R3 dcat:distribution . dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime; prov:wasDerivedFrom . pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime; prov:wasDerivedFrom . prov:wasAttributedTo . } sub:publicationInfo { sub:signature.MC0CFQCUa71N3M0l npx:hasPublicKey "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"; npx:hasSignature "MC0CFQCUa71N3M0loIwrV+fHsZHZj3xOnwIUOk0ewq/rUdTZ7/3H2KtNqLL2Htc="; npx:signedBy instance: . this: dct:created "2018-03-30T11:10:50.461+02:00"^^xsd:dateTime; dct:license ; npx:hasSignatureElement sub:signature.MC0CFQCUa71N3M0l; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dct:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }